These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19861287)

  • 41. Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Serebruany VL
    Cardiology; 2011; 120(2):84-8. PubMed ID: 22142620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the JUPITER trial on statin prescribing for primary prevention.
    Teng JF; Gomes T; Camacho X; Grundy S; Juurlink DN; Mamdani MM
    Pharmacotherapy; 2014 Jan; 34(1):9-18. PubMed ID: 23940007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Bloom JM
    Lancet; 2009 Jul; 374(9683):25-6; author reply 26-7. PubMed ID: 19577688
    [No Abstract]   [Full Text] [Related]  

  • 44. [A change of attitude in lipidology, achievement of target levels. What comes next?].
    Márk L; Dani G; Kiss Z; Katona A
    Orv Hetil; 2008 Sep; 149(37):1731-6. PubMed ID: 18805756
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Simonyi G
    Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care.
    Lee JA; Sunwoo S; Kim YS; Oh HJ; Kang HC; Park KC; Sin DH; Lee SY; Yang YJ; Yu BY; Kim CM
    Curr Med Res Opin; 2013 Jul; 29(7):751-60. PubMed ID: 23647398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
    López A; Wright JM
    Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comment from the family practice viewpoint].
    Coradi B
    Praxis (Bern 1994); 2009 Feb; 98(3):131. PubMed ID: 19180439
    [No Abstract]   [Full Text] [Related]  

  • 50. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Another look at the results of the JUPITER trial.
    Kappagoda CT; Amsterdam EA
    Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Hsia J; MacFadyen JG; Monyak J; Ridker PM
    J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Summaries for patients. Rosuvastatin to prevent heart problems and stroke in persons 70 years or older.
    Ann Intern Med; 2010 Apr; 152(8):I34. PubMed ID: 20404365
    [No Abstract]   [Full Text] [Related]  

  • 54. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
    Håkansson J
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
    [No Abstract]   [Full Text] [Related]  

  • 55. [Statin cuts cardiovascular risk in half].
    Einecke D
    MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
    [No Abstract]   [Full Text] [Related]  

  • 56. Lipid lowering for primary prevention.
    Yusuf S; Lonn E; Bosch J
    Lancet; 2009 Apr; 373(9670):1152-5. PubMed ID: 19345816
    [No Abstract]   [Full Text] [Related]  

  • 57. [JUPITER, what now?].
    Perna GP
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):33S-38S. PubMed ID: 21298860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ; Uno K; Kataoka Y
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moving toward new statin guidelines in a post-JUPITER world: principles to consider.
    Ridker PM
    Curr Atheroscler Rep; 2009 Jul; 11(4):249-56. PubMed ID: 19500487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels.
    Choudhry NK; Patrick AR; Glynn RJ; Avorn J
    J Am Coll Cardiol; 2011 Feb; 57(7):784-91. PubMed ID: 21310313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.